Tempus AI Inks Multi-Year Merck Collaboration for Oncology Biomarkers; Q4 Revenue Tops $367M
Tempus AI expanded a multi-year collaboration with Merck to leverage its de-identified data library and Lens Platform for oncology biomarker discovery, supporting novel precision medicine. In Q4, the company posted revenue of $367.21M versus consensus $362.29M and a loss of $0.04 per share, while shares fell 1.6%.
1. Multi-Year Collaboration with Merck
Tempus AI formalized a strategic collaboration with Merck to enhance discovery and development of precision medicine biomarkers. The multi-year agreement leverages Tempus’ de-identified multimodal data library and its advanced Lens Platform, supported by one of the industry’s largest GPU infrastructures, to identify novel oncology biomarkers and resistance mechanisms.
2. Q4 Financial Performance
In the quarter, Tempus AI reported revenue of $367.21 million, surpassing the consensus estimate of $362.29 million, and recorded a loss of $0.04 per share, in line with Street expectations. Year-over-year revenue rose from $200.68 million, reflecting continued uptake of its AI-driven services in clinical and research settings.
3. Stock Movement and Technical Signals
Shares of Tempus AI declined 1.6% following the announcement, underperforming broader indices that experienced sell-offs. Technical indicators show the stock trading 9.8% below its 100-day simple moving average, a neutral RSI at 44.45 and a bearish MACD signal, suggesting mixed momentum and potential support around $48.00.
4. Analyst Ratings and Price Targets
The consensus rating remains a Buy with an average price target of $74.31. Recent target revisions include JP Morgan trimming its target to $60.00, Needham lowering to $75.00 and BTIG adjusting to $90.00, indicating cautious optimism despite market headwinds.